What Increased FDA Scrutiny Means for Brands
As the FDA sharpens its focus on pharma social media advertising, the
stakes for getting it right continue to rise.
In MM+M, CG Life’s Adam Daley shares perspective on what this means for
brands—highlighting the need for clarity, balance, and a more
disciplined approach to how information shows up across channels.
